Signifor Lar Kit patents expiration

Can you believe SIGNIFOR LAR KIT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7473761 RECORDATI RARE Somatostatin analogues
Dec, 2026

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822637 RECORDATI RARE Somatostatin analogues
Aug, 2023

(a month ago)

US7759308 RECORDATI RARE Microparticles comprising somatostatin analogues
Oct, 2026

(3 years from now)

US9351923 RECORDATI RARE Extended-release composition comprising a somatostatin derivative in microparticles
May, 2028

(4 years from now)

Signifor Lar Kit is owned by Recordati Rare.

Signifor Lar Kit contains Pasireotide Pamoate.

Signifor Lar Kit has a total of 4 drug patents out of which 1 drug patent has expired.

Expired drug patents of Signifor Lar Kit are:

  • US8822637

Signifor Lar Kit was authorised for market use on 15 December, 2014.

Signifor Lar Kit is available in for suspension;intramuscular dosage forms.

Signifor Lar Kit can be used as method of treating acromegaly.

The generics of Signifor Lar Kit are possible to be released after 23 May, 2028.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 29, 2025

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

Market Authorisation Date: 15 December, 2014

Treatment: Method of treating acromegaly


More Information on Dosage

SIGNIFOR LAR KIT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic